Atlas Trials

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Clinical trial NCT05164341 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05164341
Sponsor
Chiesi Farmaceutici S.p.A.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Partial Lipodystrophy
Start date
2021-12-17
Primary completion
2026-07-21
Enrollment
69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.